Evotec's partner Exscientia reports topline data from EXS-21546 phase 1A study
13 June 2022
Evotec’s partner Exscientia plc today announced data from its Phase 1 healthy volunteer study of EXS-21546, its highly selective A2a receptor antagonist co-invented and developed through a collaboration between Exscientia and Evotec SE.